Stepan Company — 2012 Form 10-K Summary
Business context and reporting period
Fiscal year ended December 31, 2012; the filing was signed February 27, 2013. Stepan manufactures specialty and intermediate chemicals for other manufacturers. Its reportable segments are surfactants, polymers, and specialty products, representing approximately 72%, 24%, and 4% of 2012 sales, respectively. The filing also provides unaudited fourth-quarter results.
Key financial metrics
| Metric | 2012 | 2011 |
|---|---|---|
| Net sales | $1,803.7 million | $1,843.1 million |
| Gross profit / gross margin | $291.6 million / 16.2% | $255.6 million / 13.9% |
| Operating income / operating margin | $128.7 million / 7.1% | $118.5 million / 6.4% |
| Net income attributable to Stepan | $79.4 million | $72.0 million |
| Diluted EPS | $3.49 | $3.21 |
| Cash from operations | $109.0 million | $77.4 million |
| Capital expenditures | $83.2 million | $83.2 million |
| Cash and cash equivalents at year-end | $76.9 million | $84.1 million |
| Total debt at year-end | $182.4 million | $199.5 million |
| Working capital / current ratio at year-end | $275.9 million / 2.1 | $246.5 million / 2.1 |
Gross profit increased 14% as margins and volumes improved; operating expenses rose 19%, including higher deferred compensation expense. Cash from operations less capital expenditures was approximately $25.8 million. Net debt declined to $105.5 million from $115.4 million. The company had $122.4 million available under its $125 million revolving facility at year-end, with no borrowings outstanding under that facility.
Material changes versus prior comparable periods
- Annual sales declined 2%: volume increased 2%, but lower selling prices and unfavorable currency translation reduced sales by approximately $39.7 million and $39.6 million, respectively.
- Operating income rose 9% and net income attributable to Stepan rose 10%. Higher unit margins and volumes supported gross profit growth; weaker currencies reduced the year-over-year gross-profit increase by $5.2 million.
- Surfactants sales fell 4%, while segment operating income increased 18% to $118.6 million, mainly on improved margins and Brazilian production efficiencies. Polymer sales rose 1% and operating income increased 18% to $48.1 million, including benefit from a large urethane-systems sale for an aircraft carrier. Specialty Products sales increased 24% following the 2011 Lipid Nutrition acquisition, but operating income fell 8% to $12.2 million amid weaker legacy-product sales and higher support costs.
- Fourth-quarter sales were $427.3 million versus $444.2 million a year earlier; gross profit was $70.1 million versus $60.1 million; net income attributable to Stepan was $15.4 million versus $13.2 million; diluted EPS was $0.68 versus $0.58.
- The company completed a two-for-one common stock split in December 2012. Per-share figures in the filing reflect the split.
Outlook, commentary, risks and unusual items
- Management said its strategy and execution provided an opportunity for continued earnings growth in 2013, without giving numerical earnings guidance. It expected agricultural, oilfield, household and industrial cleaning opportunities to support surfactants; the Singapore plant was expected to contribute modestly in 2013.
- Management projected 2013 capital expenditures of $110–$115 million. It expected required relocation of the Nanjing, China, polymers facility to increase costs in 2013 and 2014 and constrain polymer earnings growth in 2013; the replacement plant was projected to be operational in 2015.
- Deferred compensation generated $10.2 million of expense in 2012 versus $1.5 million in 2011, largely reflecting the rise in Stepan’s share price. This accounting can cause earnings volatility. A retroactive federal R&D tax-credit extension enacted in January 2013 was expected to produce an approximately $1.25 million tax benefit in first-quarter 2013.
- Key risks include raw-material and energy-price volatility and limits on passing cost increases to customers; global competition and customer reformulations; foreign-exchange exposure; transportation or supply disruptions; facility interruptions; and environmental, product-liability and regulatory exposure.
- Environmental and legal losses were estimated at $10.3–$28.9 million, with $15.4 million accrued. The company considered its provisions adequate, but noted actual costs could differ; certain sites have unresolved or unquantifiable exposures. The Maywood site awaited an EPA Record of Decision, and the Wilmington remediation agreement has no ultimate contribution cap.
- The company reported a fifth consecutive record income year and a 45th consecutive annual dividend increase. The 2012 common dividend was $0.58 per share, up from $0.53 in 2011; debt covenants restrict dividends and share repurchases. Management reported compliance with debt agreements and expected compliance through 2013.
Important facts for investors to verify
- Whether improved margins and segment operating income can be sustained despite lower 2012 sales and higher operating expenses.
- Actual 2013 capital spending, Singapore ramp-up, and the cost, timing, and earnings impact of the China plant relocation.
- Working-capital needs, particularly the 2012 inventory increase, and the company’s capacity to fund investment and dividends while reducing debt.
- Updates to environmental and legal loss estimates, particularly Maywood and Wilmington, and any material changes in remediation obligations.
- The realized tax-credit benefit and the effect of deferred-compensation market movements on reported earnings.